UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para‐aminohippurate clearance in healthy subjects

British journal of clinical pharmacology, 2013-04, Vol.75 (4), p.990-996

2013

Volltextzugriff (PDF)

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2010-01, Vol.54 (1), p.254-258

2010

Volltextzugriff (PDF)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

Journal of acquired immune deficiency syndromes (1999), 2016-08, Vol.72 (4), p.400-407

2016

Volltextzugriff (PDF)

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

Antimicrobial Agents and Chemotherapy, 2013-08, Vol.57 (8), p.3536-3546

2013

Volltextzugriff (PDF)

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

Antimicrobial Agents and Chemotherapy, 2012-03, Vol.56 (3), p.1627-1629

2012

Volltextzugriff (PDF)

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3517-3521

2011

Volltextzugriff (PDF)

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

Antimicrobial Agents and Chemotherapy, 2013-09, Vol.57 (9), p.4394-4397

2013

Volltextzugriff (PDF)

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

Journal of clinical pharmacology, 2015-05, Vol.55 (5), p.490-496

2015

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2008-02, Vol.52 (2), p.534-538

2008

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

Journal of acquired immune deficiency syndromes (1999), 2013-01, Vol.62 (1), p.21-27

2013

Volltextzugriff (PDF)

Safety and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2007-12, Vol.51 (12), p.4284-4289

2007

Volltextzugriff (PDF)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

European journal of clinical pharmacology, 2016-06, Vol.72 (6), p.665-670

2016

Volltextzugriff (PDF)

Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food

Journal of acquired immune deficiency syndromes (1999), 2014-08, Vol.66 (4), p.393-398

2014

Volltextzugriff (PDF)

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Antimicrobial Agents and Chemotherapy, 2007-08, Vol.51 (8), p.2982-2984

2007

Volltextzugriff (PDF)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

European journal of clinical pharmacology, 2014-01, Vol.70 (1), p.29-35

2014

Volltextzugriff (PDF)

Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects

Antimicrobial agents and chemotherapy, 2014-11, Vol.58 (11), p.6696-6700

2014

Volltextzugriff (PDF)

Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery

The Annals of thoracic surgery, 2000-12, Vol.70 (6), p.2054-2063

2000

Volltextzugriff (PDF)

Expression, localisation and function of ACE and chymase in normal and atherosclerotic human coronary arteries

Vascular pharmacology, 2005-02, Vol.42 (3), p.99-108

2005

Volltextzugriff (PDF)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

British journal of clinical pharmacology, 2014-11, Vol.78 (5), p.1043-1049

2014

Volltextzugriff (PDF)

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

Journal of antimicrobial chemotherapy, 2011-07, Vol.66 (7), p.1567-1572

2011

Volltextzugriff (PDF)

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next‐generation HIV integrase inhibitor, S/GSK1349572

British journal of clinical pharmacology, 2011-07, Vol.72 (1), p.103-108

2011

Volltextzugriff (PDF)

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics

Pharmacogenomics, 2014-01, Vol.15 (1), p.9-16

2014

Volltextzugriff (PDF)

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol

The Annals of pharmacotherapy, 2015-07, Vol.49 (7), p.784-789

2015

Volltextzugriff (PDF)

Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts

The Journal of thoracic and cardiovascular surgery, 1998-08, Vol.116 (2), p.206-212

1998

Volltextzugriff (PDF)

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

Journal of clinical pharmacology, 2011-02, Vol.51 (2), p.237-242

2011

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(61)

Publikationsform

Sprache

Englisch
(79)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(63)
Humans
(60)
Male
(47)
Female
(42)
Adult
(40)
Middle Aged
(39)
Biological And Medical Sciences
(27)
Pharmacology & Pharmacy
(26)
Medical Sciences
(23)
Adolescent
(19)
Hiv Integrase Inhibitors - Pharmacokinetics
(17)
Heterocyclic Compounds, 3-Ring - Pharmacokinetics
(16)
Aged
(15)
Drug Interactions
(15)
Area Under Curve
(14)
Pharmacology. Drug Treatments
(14)
Cardiovascular System & Cardiology
(13)
Human Immunodeficiency Virus
(13)
Microbiology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para‐aminohippurate clearance in healthy subjects

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

Safety and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects

Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery

Expression, localisation and function of ACE and chymase in normal and atherosclerotic human coronary arteries

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next‐generation HIV integrase inhibitor, S/GSK1349572

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol

Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

Suchergebnisse filtern